colistimethate sodium 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | PK/Tox | Related Drugs | BioActivity |

Stem definitionDrug idCAS RN
731 8068-28-8

Description:

MoleculeDescription

Synonyms:

  • colistimethate
  • colistimethate sodium
  • colistinmethanesulfonic acid
  • Colimycin M
  • Colimycin sodium methanesulfonate
  • colistin sulfomethate
  • colistin sodium methanesulfonate
  • pentasodium colistinmethanesulfonate
  • colistin sulphomethate
  • colobreathe
  • Molecular weight: 3485.59
  • Formula: C115H208N32Na10O56S10
  • CLOGP:
  • LIPINSKI: None
  • HAC: None
  • HDO: None
  • TPSA: 706.71
  • ALOGS:
  • ROTB: None

Drug dosage:

None

ADMET properties:

None

Predicted pharmacokinetic/toxicological properties (PK-AZ):

None

Approvals:

DateAgencyCompanyOrphan
June 4, 1970 FDA PAR STERILE PRODUCTS

FDA Adverse Event Reporting System (Female)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Infective pulmonary exacerbation of cystic fibrosis 203.72 35.72 45 1562 10234 90616606
Pathogen resistance 109.47 35.72 26 1581 8089 90618751
Multiple organ dysfunction syndrome 94.57 35.72 38 1569 68298 90558542
Amniotic fluid index increased 83.56 35.72 11 1596 104 90626736
Foetal macrosomia 66.97 35.72 10 1597 247 90626593
Left-to-right cardiac shunt 66.04 35.72 10 1597 272 90626568
Acute kidney injury 65.05 35.72 50 1557 320337 90306503
Pseudo-Bartter syndrome 59.26 35.72 8 1599 93 90626747
Pelvic kidney 58.36 35.72 8 1599 105 90626735
Hospitalisation 57.88 35.72 33 1574 128067 90498773
Septic shock 55.81 35.72 28 1579 84132 90542708
Cystic fibrosis 44.76 35.72 11 1596 3930 90622910
Abscess neck 43.11 35.72 8 1599 753 90626087
Sepsis syndrome 41.15 35.72 8 1599 965 90625875
Skin maceration 38.10 35.72 6 1601 212 90626628
Pseudomonas infection 37.99 35.72 13 1594 14852 90611988
Renal failure 36.89 35.72 25 1582 130982 90495858

FDA Adverse Event Reporting System (Male)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Infective pulmonary exacerbation of cystic fibrosis 147.04 42.74 37 1386 7781 42612131
Acute kidney injury 82.03 42.74 79 1344 367258 42252654
Eosinophilia 80.75 42.74 33 1390 32866 42587046
Leukocytosis 80.50 42.74 32 1391 29676 42590236
Hepatic cytolysis 69.53 42.74 28 1395 26816 42593096
Pseudo-Bartter syndrome 54.98 42.74 7 1416 23 42619889
Rash maculo-papular 54.33 42.74 26 1397 37477 42582435
Septic shock 53.71 42.74 35 1388 91637 42528275
Hospitalisation 50.05 42.74 31 1392 74299 42545613
Pseudomonas infection 49.60 42.74 19 1404 15904 42604008
Pathogen resistance 44.22 42.74 16 1407 11434 42608478

FDA Adverse Event Reporting System (Geriatric)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Infective pulmonary exacerbation of cystic fibrosis 241.28 36.02 59 2709 14712 110571819
Pathogen resistance 145.44 36.02 41 2727 17631 110568900
Acute kidney injury 142.47 36.02 121 2647 635309 109951222
Multiple organ dysfunction syndrome 107.21 36.02 59 2709 151651 110434880
Septic shock 97.03 36.02 56 2712 157472 110429059
Pseudo-Bartter syndrome 96.10 36.02 13 2755 105 110586426
Amniotic fluid index increased 72.56 36.02 10 2758 94 110586437
Leukocytosis 70.88 36.02 32 2736 53796 110532735
Eosinophilia 68.63 36.02 32 2736 57904 110528627
Cystic fibrosis 67.61 36.02 17 2751 4714 110581817
Hospitalisation 65.41 36.02 42 2726 142451 110444080
Nephropathy toxic 58.50 36.02 23 2745 27455 110559076
Hepatic cytolysis 57.83 36.02 28 2740 55025 110531506
Foetal macrosomia 56.34 36.02 8 2760 95 110586436
Pseudomonas infection 54.72 36.02 22 2746 27831 110558700
Rash maculo-papular 52.68 36.02 29 2739 74193 110512338
Renal failure 52.09 36.02 44 2724 226530 110360001
Left-to-right cardiac shunt 50.99 36.02 8 2760 193 110586338
Drug resistance 42.69 36.02 23 2745 56351 110530180
Sepsis syndrome 39.81 36.02 9 2759 1587 110584944
Lung transplant 37.78 36.02 11 2757 5275 110581256
Haemoptysis 37.65 36.02 23 2745 71331 110515200

FDA Adverse Event Reporting System (Pediatric)

None

Pharmacologic Action:

SourceCodeDescription
FDA CS M0017217 Polymyxins
FDA EPC N0000175499 Polymyxin-class Antibacterial
CHEBI has role CHEBI:33281 antimicrobial agent
CHEBI has role CHEBI:33282 antibacterial agent
CHEBI has role CHEBI:35441 antiinfective agent
CHEBI has role CHEBI:50266 prodrug

Drug Use | Suggest Off label Use Form| |View source of the data|

DiseaseRelationSNOMED_IDDOID
Infection due to Escherichia coli indication 71057007
Pseudomonas Aeruginosa Infections indication
Klebsiella Infections indication
Pseudomonas Respiratory Tract Infection in Cystic Fibrosis indication
Enterobacter Infection indication
Neuromuscular block, function contraindication 55394004
Kidney disease contraindication 90708001 DOID:557
Myasthenia gravis contraindication 91637004 DOID:437
Pseudomembranous enterocolitis contraindication 397683000




🐶 Veterinary Drug Use

SpeciesUseRelation
Chickens Control of early mortality associated with Escherichia coli Indication

🐶 Veterinary products

ProductApplicantIngredients
First Guard Sterile Powder Zoetis Inc. 1

Acid dissociation constants calculated using MoKa v3.0.0

None

Orange Book patent data (new drug applications)

None

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

None

External reference:

IDSource
4019694 VUID
N0000147786 NUI
D02049 KEGG_DRUG
12705-41-8 SECONDARY_CAS_RN
2708 RXNORM
C0110462 UMLSCUI
CHEBI:34650 CHEBI
CHEMBL1201441 ChEMBL_ID
CHEMBL6067483 ChEMBL_ID
C004691 MESH_SUPPLEMENTAL_RECORD_UI
5642 INN_ID
XW0E5YS77G UNII
44585614 PUBCHEM_CID
DB01111 DRUGBANK_ID
41658 MMSL
4495 MMSL
d01113 MMSL
002805 NDDF
017469 NDDF
38686006 SNOMEDCT_US
422267005 SNOMEDCT_US
82885001 SNOMEDCT_US
4018653 VANDF
4019694 VANDF
XW0E5YS77G INXIGHT DRUGS

Pharmaceutical products:

ProductCategoryIngredientsNDCFormQuantityRouteMarketingLabel
Colistimethate HUMAN PRESCRIPTION DRUG LABEL 1 0143-9443 INJECTION, POWDER, FOR SOLUTION 150 mg INTRAMUSCULAR ANDA 23 sections
COLISTIMETHATE SODIUM HUMAN PRESCRIPTION DRUG LABEL 1 23155-193 INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION 150 mg INTRAMUSCULAR ANDA 20 sections
Coly-MycinM HUMAN PRESCRIPTION DRUG LABEL 1 42023-107 INJECTION 150 mg INTRAMUSCULAR NDA 22 sections
Colistimethate Human Prescription Drug Label 1 63323-393 INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION 150 mg INTRAMUSCULAR ANDA 12 sections
Colistimethate HUMAN PRESCRIPTION DRUG LABEL 1 70594-023 INJECTION, POWDER, FOR SOLUTION 150 mg INTRAVENOUS ANDA 23 sections
Colistimethate HUMAN PRESCRIPTION DRUG LABEL 1 70594-023 INJECTION, POWDER, FOR SOLUTION 150 mg INTRAVENOUS ANDA 23 sections